News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zonagen (ZONA) Announces U.S. IND For The Study Of Proellex(TM) In The Treatment Of Uterine Fibroids Has Become Effective


12/16/2005 1:12:00 PM

Zonagen, Inc. (Nasdaq:ZONA)(PCX:ZONA) today announced that the Company's IND for the U.S. study of its drug Proellex(TM) has become effective on December 14, 2005. The study will enroll 150 patients at up to 20 clinical sites in the United States.

Read at BioSpace.com

comments powered by Disqus
Zonagen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES